Novartis files CAR-T therapy in US, with swift review – PMLiVE
|
Novartis files CAR–T therapy in US, with swift review
PMLiVE In CAR-T therapy, patients' cells are harvested and modified so they are more likely to seek out and destroy cancer cells expressing a particular antigen, in this case CD19. Once reprogrammed, the T cells are infused back into the patient in order to … |
